Why Mirum Pharmaceuticals, Inc. (MIRM) stock moved
Mirum Pharmaceuticals, Inc. (MIRM) shares rose 1.5% to $87.03 as of November 3, 2026, a modest gain from the prior close of $85.74. BestStocks flagged the session as a major change for MIRM. The move is tied to an earnings miss. Below, we break down what changed for MIRM, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Earnings Miss
Mirum Pharmaceuticals, Inc. (MIRM) reported EPS of −$0.87 vs. consensus estimate of −$0.49, missing by 78.7% on 2026-11-03. MIRM's next earnings are scheduled for 2027-02-24, with consensus EPS estimate of −$0.58.
What it means for Mirum Pharmaceuticals, Inc. investors
For Mirum Pharmaceuticals, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Positive 1.5% session move; Mirum Pharmaceuticals, Inc. (MIRM) moved +5.49% from $95.41 to $100.65 on 2026-08-07. Weighing against that: Earnings missed expectations; Mirum Pharmaceuticals shares fell 5.85% to $93.04 as investors weigh regulatory uncertainties ahead of a September 26 FDA decision on zilurgisertib for FOP and recent FDA requests for additional Phase 3 clarity on volixibat, according to the web_catalyst synthesis. Wall Street's consensus price target sits at $153.20, implying +76.0% upside from $87.03. BestStocks rates the overall signal quality low (55/100). With earnings roughly 113 days out, the next report is the most likely near-term test of the move.
MIRM price reaction
MIRM last traded at $87.03, up $1.29 (+1.50%) from the previous close of $85.74. The session traded on 0.9× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $79.25 and $87.03, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Mirum Pharmaceuticals, Inc. (MIRM)
The consensus analyst price target on Mirum Pharmaceuticals, Inc. (MIRM) is $153.20, 76.0% above the recent $87.03. Over the past 90 days analysts logged 0 upgrades, 15 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MIRM line up.
The bullish case
- Wall Street's consensus price target of $153.20 implies +76.0% upside from $87.03.
- The Street's most bullish target is $200.00 (+129.8%).
- Positive 1.5% session move.
- Mirum Pharmaceuticals, Inc. (MIRM) moved +5.49% from $95.41 to $100.65 on 2026-08-07.
The bearish case
- Earnings missed expectations.
- Mirum Pharmaceuticals shares fell 5.85% to $93.04 as investors weigh regulatory uncertainties ahead of a September 26 FDA decision on zilurgisertib for FOP and recent FDA requests for additional Phase 3 clarity on volixibat, according to the web_catalyst synthesis.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 3, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for MIRM
In-depth MIRM event analyses
Frequently asked questions about MIRM
Why did Mirum Pharmaceuticals, Inc. (MIRM) stock move?
MIRM rose 1.5% to $87.03. The move is associated with an earnings miss.
How much did MIRM stock rise?
MIRM gained 1.50% ($1.29) versus the prior close of $85.74, last trading at $87.03 on 0.9× average volume.
When is Mirum Pharmaceuticals, Inc.'s next earnings date?
MIRM's next earnings report is estimated for 2027-02-24 — about 113 days away.
What is the analyst price target for MIRM?
The consensus analyst price target for MIRM is $153.20, about 76.0% above the current $87.03. Over the past 90 days, analysts recorded 0 upgrades, 15 maintains, and 0 downgrades.
How BestStocks tracks MIRM
This page is generated automatically by BestStocks' change-detection system after an earnings miss was detected and verified against independent data sources. It draws on 20 tracked change events for MIRM, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 3, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.